HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target
10/19/2026
Impact: 70
Healthcare
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Clene (NASDAQ: CLNN) and maintained a price target of $31 for the company's stock.
AI summary, not financial advice
Share: